Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07408193 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Role of Coadministration of Lidocaine and Ketamine in Opioid-Refractory Chronic Cancer-Related Pain.

StatusRecruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Start date changed from estimate of Mar 2026 to Mar 1, 2026 · Site details revisedv3 Show 2 more changesShow less
    • Start date changed from estimate of Mar 2026 to Mar 1, 2026
    • Site details revised
  2. Secondary endpoints: details revised at 2 of 7 entries Eligibility criteria shortened, about 1 word · Study description expanded, about 1 wordv2 Show 2 more changesShow less
    • Eligibility criteria shortened, about 1 word
    • Study description expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a randomized, double-blinded, placebo-controlled, cross-over trial examining the effect of a series of two weekly intravenous infusions of lidocaine 4 mg/kg and ketamine 0.2 mg/kg in patients with moderate to severe opioid-refractory chronic cancer-related pain. The aim of this study is to investigate whether the lidocaine - ketamine (LK) regimen provides better analgesia that an active placebo of midazolam 0.02 mg/kg, in this population.
Trial Details
NCT Number NCT07408193
Lead Sponsor National and Kapodistrian University of Athens
Collaborators: Attikon Hospital
Conditions Opioid-Refractory Chronic Cancer-Related Pain
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov